Bernard Daugeras
Oprichter bij Auriga Partners SA
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Sébastien Descarpentries | M | 50 |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France.
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | 25 jaar |
Philippe Peltier | M | 52 |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France.
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | 17 jaar |
Patrick Bamas | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 25 jaar |
Franck Lescure | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France.
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | 15 jaar |
Hüseyin Firat | M | - |
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | 16 jaar |
François Vix | M | - |
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | 23 jaar |
Florian Denis | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France.
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | 2 jaar |
Jacques Mallet | M | 64 |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | 7 jaar |
Jacques Chatain | M | 70 |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 25 jaar |
Philippe Granger | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 25 jaar |
Marjorie Sidhoum | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 11 jaar |
Bernard Gilly | M | 67 |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | 10 jaar |
Luca Verre | M | 43 |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | 10 jaar |
Michael Gustav Brock | M | - | 9 jaar | |
Olivier Danos | M | 66 |
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | 12 jaar |
Patricia Zerr | F | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Nathalie Lenne | F | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Guy Le Houillier | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Geoffroy Rosset | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 7 jaar |
Sylvie Ryckebusch | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Brigitte Kieffer | F | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Gilles Feutren | M | - |
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | - |
Celine Lippi | F | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 5 jaar |
Christel Franchet | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Béatrice Molac | M | - |
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | - |
Emmanuelle Coutanceau | M | 44 |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 10 jaar |
Sébastien Groyer | M | 44 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 12 jaar |
Stephan Schann | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 jaar |
Jean-Denis Voin | M | - |
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | - |
Michel Ronc | M | 79 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 jaar |
Alain Goetzmann | M | - |
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | - |
Joanne Marie Sawicki | F | - |
Isocell SA
Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | - |
Philippe Desmarescaux | M | 85 |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | - |
Jonathan Treherne | M | 63 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 jaar |
Yvan Devaux | M | - |
Firalis SA
Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Pascal Neuville | M | 60 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 jaar |
Tom Egelund | M | - | 1 jaar | |
Nicolas Tcherdakoff | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 6 jaar |
Alexia Perouse | F | - | - | |
Anthony G. Johnson | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Johannes Barella | M | 81 | 6 jaar | |
Sabine Lochmann-Beaujour | F | - | - | |
François Lainée | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 10 jaar |
Gordon Waldron | M | - | 5 jaar | |
Kurt Kelln | M | 62 | 6 jaar | |
Isabelle Senéterre | F | - |
Crédit Lyonnais SA
Crédit Lyonnais SA Major BanksFinance Crédit Lyonnais SA provides banking and financial services. Its activities include banking for individuals and professionals, private banking, franchise and associate commerce, and corporate banking and asset management. The company was founded by Henri Germain on July 6, 1863 and is headquartered in Lyon, France. | 21 jaar |
Christophe Sibillin | M | - | - | |
Dounia Taarji | F | - |
Crédit Lyonnais SA
Crédit Lyonnais SA Major BanksFinance Crédit Lyonnais SA provides banking and financial services. Its activities include banking for individuals and professionals, private banking, franchise and associate commerce, and corporate banking and asset management. The company was founded by Henri Germain on July 6, 1863 and is headquartered in Lyon, France. | 3 jaar |
Aurélie Gruener | M | - | - | |
Youssef Bennani | M | 63 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 10 jaar |
François Valencony | M | - | - | |
Jérôme Alexis Louis Nanty | M | 63 |
Crédit Lyonnais SA
Crédit Lyonnais SA Major BanksFinance Crédit Lyonnais SA provides banking and financial services. Its activities include banking for individuals and professionals, private banking, franchise and associate commerce, and corporate banking and asset management. The company was founded by Henri Germain on July 6, 1863 and is headquartered in Lyon, France. | 15 jaar |
Aline Criton | M | - | - | |
Thomas C. Seoh | M | 66 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 2 jaar |
Rodolphe Lilamand | M | - |
Auriga Partners SA
Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | 5 jaar |
Michèle Debain | F | - | - | |
Anne-Sophie Herelle | F | 43 | - | |
Olivier Litzka | M | 56 | - | |
Aris Constantinides | M | 77 | - | |
Philippe Boucheron | M | - | 9 jaar | |
Louis Joseph Nisbet | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Maurice Israel | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Yves Dunant | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Pierre Potier | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Georges Charpak | M | 100 | 5 jaar | |
Bradley G. Garrett | M | - | - | |
Tom Francke | M | - | 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Frankrijk | 67 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Bernard Daugeras
- Persoonlijk netwerk